Laurion Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Laurion Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-824,380	Closed	-$31.7M	–	729
2023 Q2	$31.7M	Sell	824,380 -5,370	-0.6%	-$138K	0.18%	115
2023 Q1	$19.2M	Hold	829,750	–	–	0.13%	148
2022 Q4	$21.7M	Buy	829,750 +643	+0.1%	+$14.2K	0.1%	165
2022 Q3	$16.3M	Sell	829,107 -643	-0.1%	-$12.9K	0.1%	154
2022 Q2	$14.5M	Buy	829,750 +75,000	+10%	+$1.18M	0.22%	89
2022 Q1	$12.3M	Buy	754,750 +200,500	+36%	+$2.73M	0.15%	98
2021 Q4	$9.04M	Buy	+554,250	New	+$7.89M	0.09%	143
2016 Q2	–	Sell	-4,880	Closed	-$313K	–	1079
2016 Q1	$313K	Buy	+4,880	New	+$395K	﹤0.01%	584

Laurion Capital Management's KDNY Position: Q3 2023 in Review

Laurion Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 824,380 shares — an estimated $31.7M sold.

Laurion Capital Management first reported a position in KDNY in Q1 2016 and held it in 8 quarters. The position peaked at $31.7M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Laurion Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Laurion Capital Management sold 824,380 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $31.7M.
Laurion Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2016 and held it in 8 quarters.
Laurion Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $31.7M in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Laurion Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.